ArticleFrontiers in veterinary science2025
Evaluation of urine glutathione peroxidase 4 in cats with chronic kidney disease.
Article in Frontiers in veterinary science, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Ferroptosis is a distinct form of regulated cell death characterized by iron-dependent lipid peroxidation that damages cellular membranes and leads to the end of a cell's life. Glutathione peroxidase 4 (GPX4), the only enzyme capable of the reduction of lipid peroxidation products within cells, is a key regulator of this process. Aims: The role of GPX4 in feline chronic kidney disease (CKD) has not been previously investigated. This study aims to determine whether urine GPX4 levels are associated with CKD severity in cats and to assess their potential as a progression biomarker. Methods: Urine GPX4 levels were measured using a commercial feline ELISA kit. The urine-GPX4-to-creatinine ratio (UGCR) was calculated. Fifteen healthy cats, 61 cats with CKD, and six cats with acute-on-chronic kidney disease (ACKD) were included in the study. Results: Compared with the control group (urine GPX4, median [IQR]: 25.21 [18.99-26.91]; UGCR: 0.072 [0.057-0.101] × 10 Conclusion and clinical importance: UGCR increased with the severity of CKD and was significantly associated with serum creatinine concentration and disease progression. Urine GPX4 may thus serve as a novel biomarker for monitoring renal deterioration and progression in cats with CKD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.